Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total value of $43,500.00. Following the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,247,420. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, June 17th, Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $19.00, for a total transaction of $41,344.00.
• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Stock Up 3.9%

Shares of NASDAQ GLUE opened at $21.66 on Friday. Monte Rosa Therapeutics, Inc. has a 12 month low of $4.12 and a 12 month high of $25.77. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -14.64 and a beta of 1.60. The business has a fifty day simple moving average of $18.88 and a 200-day simple moving average of $18.61.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, sell-side analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GLUE has been the topic of several research analyst reports. Wells Fargo & Company lowered their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. JPMorgan Chase & Co. lifted their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Guggenheim cut their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth approximately $30,000. Nisa Investment Advisors LLC increased its position in Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in Monte Rosa Therapeutics in the 4th quarter valued at $63,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $32,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.